Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

DisCoVeRy (remdesivir)
 
NCT04315948
RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
429/428 no results
Mahajan RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
41/41 inconclusive 21%
NIH NIAID ACTT-1
 
NCT04280705
RCTremdesivirplaceboCOVID 19 hospitalizedsome concern
541/521 suggested -40% 26%
SOLIDARITY (remdesivir)
 
NCT04315948
RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
2750/2725 inconclusive -5% -3%

COVID 19 all comers meta-analysis

Andreas (NOR-Solidarity)
 
NCT04321616
RCTremdesivirCOVID 19 all comerslow
43/58 ongoing
Norwegian NOR study (remdesivir)
 
NCT04321616
RCTremdesivirstandard of careCOVID 19 all comerssome concern
43/58 no results

COVID-19 mild to moderate meta-analysis

GS-US-540-5773 (Goldman)
 
NCT04292899
RCTremdesivirremdesivirCOVID-19 mild to moderatesome concern
200/197 suggested -24% -19%
GS-US-540-5774, 10 days
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
197/200 safety concern -22% 14%
GS-US-540-5774, 5 days
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
199/200 conclusif -44% demonstrated58%

COVID-19 severe or critically meta-analysis

CAP-China (Wang et al.)
 
NCT04257656
RCTremdesivirplaceboCOVID-19 severe or criticallylow
158/79 inconclusive 9% 21%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).